

IntelGenx Technologies Corp.  
Form 8-K  
February 09, 2017

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549 FORM 8-K**

**Current Report**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**February 9, 2017**  
Date of Report (Date of Earliest Event Reported)

**IntelGenx Technologies Corp.**  
(Exact Name of Registrant as Specified in its Charter)

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>000-31187</b> (Commission File Number)	<b>870638336</b> (IRS Employer Identification No.)
--	---	--

6420 Abrams, Ville St- Laurent, Quebec, Canada (Address of principal executive offices)	H4S 1Y2 (Zip Code)
--	-----------------------

Registrant's telephone number, including area code: (514) 331-7440

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
  - Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

**Item 8.01 Other Events - News Release**

**IntelGenx and Tetra Bio-Pharma Announce the Commercialization and Development Term Sheet for a Pharmaceutical based Cannabis Tablet**

Exhibit	Description
<u>99.1</u>	<u>Press Release</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTELGENX TECHNOLOGIES CORP.**

Dated: February 9, 2017

By: */s/ Horst G. Zerbe*

-----  
Horst G. Zerbe

President and Chief Executive Officer

---